A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2622829
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen.
Primary outcome(s): Progression-free Survival
Study Design: Single arm Non-randomized
创建时间：
2012-04-15
